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Summary Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected
individuals, is generally treated with high doses of co-trimoxazole. However, treatment is often
limited by adverse effects. Here, we report two cases of severely immunocompromised HIV-
infected patients who developed severe intrahepatic cholestasis, and in one patient lesions
mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.
Whereas patient 1 showed lesions of up to 1 cm readily detectable onmagnetic resonance imaging
under prolonged co-trimoxazole treatment, therapy of patient 2 was switched early.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
The incidence of opportunistic infections in HIV-positive
patients has dramatically decreased since the arrival of
highly active antiretroviral therapy (HAART) regimens. How-
ever, Pneumocystis pneumonia (PCP) remains one of the
most frequent opportunistic infections and a leading cause
of death in severely immunocompromised HIV-infected
patients.1,2 The preferred drug therapy for severe PCP is
co-trimoxazole (trimethoprim—sulfamethoxazole). Due to
the high doses necessary in PCP, treatment is often limited
by severe side effects such as hepatotoxicity, rash, anemia,
thrombocytopenia, and neutropenia. Here, we report the
cases of two young HIV-infected patients who developed liver* Corresponding author.
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doi:10.1016/j.ijid.2008.12.016toxicity and lesions mimicking liver abscesses during co-
trimoxazole treatment for PCP.
Case 1
A 24-year-old Asian male was admitted to our hospital with
atypical pneumonia, rapid respiratory deterioration, and
progressive pulmonary infiltrates. A diagnosis of advanced
HIV-infection with a CD4 cell count of 15/ml and a viral load of
46 000 copies/ml wasmade. Bronchoalveolar lavage revealed
Pneumocystis jirovecii and treatment was initiated with
trimethoprim—sulfamethoxazole (co-trimoxazole; 20 mg tri-
methoprim per kg) IV and 50 mg prednisolone. The patient
developed respiratory failure after 10 days requiring
mechanical ventilation for 14 days. Antiretroviral therapy
with nelfinavir, stavudine, and lamivudine was initiated after
clinical recovery and extubation.Published by Elsevier Ltd. All rights reserved.
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transferase (ALT) with a maximum of 180 U/l (normal <22)
combinedwith an elevated alkaline phosphatase (ALP) of 1414
U/l (normal<170) and a bilirubin of 1.3 mg/dl (normal<1.0).
No obstructive cholestasis could be detected by sonography.
Further investigation showed cytomegalovirus (CMV) viremia
(with a viral load of 100—1000 CMV copies/ml in peripheral
blood), and additional therapy with ganciclovir IV was
initiated. PCP therapy was switched to prophylactic dosing,
accompanied by further improvement of the patient’s condi-
tion. However, cholestasis parameters remained elevated.
The further clinical course was complicated by Candida eso-
phagitis and generalized seizure (without abnormalities in
computed tomography (CT) or liquor).
Eight weeks after initial admission, while on co-trimox-
azole prophylaxis for PCP, the patient developed jaundice
and fever up to 40 8C (leukocyte count 14.3  109/l , ALT 63
U/l, ALP 964 U/l, bilirubin 3.3 mg/dl). Both sonography and
magnetic resonance (MR) tomography showed lesions
mimicking liver abscess formation with diameters of up to
1.3 cm (Figure 1). Two subsequent biopsies of the intrahe-
patic lesions did not reveal liver abscesses and did not show
any pathogens. Histology revealed cholestasis and cholangitis
with mild hepatitis compatible with toxic liver damage. TheFigure 1 Magnetic resonance tomography showing intrahepa-
tic lesions, especially in the right lobe (patient 1).size of the lesions and ALP values slowly decreased after
adding ursodeoxycholic acid and without any further change
in therapy. Co-trimoxazole prophylaxis was stopped after 11
months with rising CD4 counts of >300/ml.
During the following clinical visits, the patient continued
to have elevated ALT and ALP values without jaundice or
other changes in his general condition, whereas MR tomo-
graphy showed a significant reduction of liver lesions (both in
size and number). After a follow-up of 4 years, laboratory
values have declined further with an ALT of 185 U/l and an
ALP of 319 U/l.
Case 2
A 24-year-old Caucasian male was admitted to our intensive
care unit (ICU) with PCP and further respiratory deterioration
under mechanical ventilation. Co-trimoxazole treatment
(20 mg trimethoprim per kg IV) had already been initiated.
Subsequent tests revealed advanced HIV-infection with an
initial CD4 count of 2/ml and a viral load of 91 000 copies/ml.
After a complicated clinical course with bilateral pneu-
mothorax he gradually recovered, and antiretroviral therapy
with zidovudine, lamivudine, and boostered lopinavir was
started after significant improvement of his respiratory situa-
tion. Similar to case 1, severe Candida esophagitis and gen-
eralized seizures without any detectable abnormalities in CT
occurred as further complications.
After 14 days at the ICU, he developed jaundice and liver
value abnormalities, with an ALT of up to 381 U/l and an
elevated ALP of 4351 U/l without obstructive cholestasis
being detectable by ultrasound examination. Endoscopic
cholangiography was suggestive of secondary sclerosing cho-
langitis. Having a viral load of 10 000 CMV copies/ml in
peripheral blood, therapy with ganciclovir was added. Liver
biopsy showed infiltration by granulocytes, mild cholangitis,
cholestasis, and a centrilobular microabscess formation,
whereas all microbiological diagnostics (including Grocott
staining for fungi and PCR for Pneumocystis, Candida, and
CMV) failed to detect any intrahepatic pathogens. Because of
suspected drug-related liver toxicity, all drug treatments
possibly implicated were terminated or changed. Co-trimox-
azole was initially substituted with atovaquone and later
changed to dapsone. ALP values reached a maximum of
8133 U/l with a bilirubin of 18.9 mg/l.
Within the next 8 weeks, the patient was intermittently re-
admitted to the ICU and eventually required mechanical
ventilation due to recurrent pneumothoraces. After improve-
ment in his general condition, he was sent to a rehabilitation
institution with laboratory values of ALT 74 U/l, ALP 2261 U/l,
and bilirubin of 13 mg/l. TheCD4 countwas 15/ml and the viral
load 100 copies/ml. However, 6 months after initial admission
he was re-admitted to the hospital due to general clinical
deterioration and died shortly thereafter of sepsis with multi-
ple organ failure; an autopsy was declined by the relatives.
Discussion
PCP remains one of the most common opportunistic infections
in HIV-infected patients. Severe PCP with respiratory failure
eventually requiring mechanical ventilation is associated
with a high mortality (exceeding 60% in some studies).3 The
most effective treatment for severe PCP is co-trimoxazole.
Cholestasis after high-dose co-trimoxazole for PCP e469Alternatively, pentamidinemay be used, but this is considered
a second-line agent due to serious adverse effects.
However, the use of co-trimoxazole is often limited by
toxicity. Most frequent are rash, drug fever, liver function
abnormalities, anemia, neutropenia, and thrombocytope-
nia.4,5 The rate of side effects experienced by HIV-infected
patients appears to be considerably higher than in the gen-
eral population (24—83% vs. 8%4,6—8). Hepatotoxicity with
elevated liver enzymes is a well-known side effect of co-
trimoxazole. Other reports have associated the drug with
cholestatic liver disease9,10 and pancreatitis,11—13 and rarely
a vanishing bile duct syndrome following the administration
of co-trimoxazole9,14 has been described. However, to the
best of our knowledge, only one previous anecdotal report of
focal hepatic lesions in combination with co-trimoxazole
treatment has been published.15
The two patients presented here had severe PCP and were
seriously immunocompromised (reflected by low CD4 count,
Candida esophagitis, and CMV reactivation). Both developed
liver enzyme alterations (elevated ALTwith more pronounced
elevations in ALP and bilirubin) within days after onset of
high-dose IV co-trimoxazole therapy, initially without detect-
able liver abnormalities on sonography. Patient 2 (with a
more fulminant course and higher liver enzymes) had a liver
biopsy performed early in the course of disease, which
yielded hepatitis, cholestasis, and cholangitis with micro-
abscess formation and infiltration by granulocytes. Liver
lesions suggesting abscess formation in severely immunocom-
promised patients may present a diagnostic challenge. The
differential diagnosis includes secondary bacterial and other
opportunistic infections, such as mycobacteria and invasive
candidiasis; rarely even Pneumocystis jirovecii infection of
the liver has been reported.16,17 Thus, it appears crucial to
exclude infectious complications before diagnosing a drug-
related adverse event. Surprisingly, both patients had CMV
infection diagnosed at the time of liver lesions. However,
since PCR was negative, CMV infection as the main cause of
liver lesion formation appears unlikely. Chronic disseminated
candidiasis might present with similar clinical features and
might be visible for years. However, both patients were
already receiving fluconazole treatment for Candida esopha-
gitis, and liver biopsies failed to detect fungi. We cannot rule
out Pneumocystis itself as a causative agent, at least for
patient 1. However, PCR for Pneumocystis was negative in a
liver biopsy performed in patient 2. Furthermore, the con-
tribution of other drugs administered during the ICU stay
(e.g., sedatives) remains unclear.
For patient 2, all hepatotoxic drugs (including co-trimox-
azole) were switched immediately, which was feasible due to
the ameliorating pneumonia. Hereafter, cholestasis para-
meters declined. The fatal outcome most likely has to be
attributed to immunosuppression (CD4 count still below 50/
ml) and his compromised general condition with critical care
illness and several recurrent pneumothoraces. In contrast,
patient 1 continued to be on co-trimoxazole treatment
despite elevated liver enzymes. Lesions suggesting abscess
formation were discovered by MR tomography several weeks
later, after an episode of fever, with diameters of more than
1 cm (Figure 1). The long exposure to co-trimoxazole may
well be responsible for the protracted and more severe
course. The lesions were still detectable several years later
on abdominal sonography.In summary, lesions suggesting liver abscess formation
may be due to cholestatic hepatotoxicity in patients treated
with high doses of co-trimoxazole for severe PCP. Patients
should bemonitored carefully and a switch of therapy may be
an option when rising liver enzymes and/or cholestasis para-
meters are observed.
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